Pictured: Chau T. Dang, MD

Chau T. Dang, MD

Medical Oncologist

Titles

Regional Care Network Medical Site Director, MSK Westchester

Clinical Expertise

Breast Cancer

New Patient Appointments

Scheduling a visit is easy. Click below or call us to get started.

Accepted Insurance Providers

Dr. Dang accepts the following list of insurance providers. Select your insurance provider to see more details.

Contact and Location

Locations map

Find a Convenient Location

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offers many services, including screening, chemotherapy, and medical testing.

About Me

Education

MD, Medical University of South Carolina

Residencies

Internal Medicine - Allegheny General Hospital/Medical College of Pennsylvania

Fellowships

Hematology/Oncology - Memorial Sloan Kettering Cancer Center

Board Certifications

Internal Medicine; Medical Oncology

I am a board-certified medical oncologist and work as part of a multidisciplinary team to care for patients with breast cancer. In my clinical research I focus on developing more-effective and less-toxic treatment strategies for women with this disease. My particular interest is in evaluating combination therapies that include anti-HER2 drugs with chemotherapy in the treatment of patients with early-stage and metastatic HER2-positive breast cancer.

My research has changed standard practice. For example, the widespread use and National Comprehensive Cancer Network (NCCN) endorsement of a dose-dense, anthracycline/taxane-containing chemotherapy regimen followed by trastuzumab in patients with early stage HER2-positive breast cancer was a direct consequence of an investigator-initiated trial that I led at Memorial Sloan Kettering. Additionally, I led another investigator-initiated study that evaluated dual anti-HER therapy with trastuzumab and pertuzumab and chemotherapy for patients with HER2-positive metastatic breast cancer. This led to the NCCN endorsement of this regimen as a standard option in treating patients with metastatic HER2-positive breast cancer. A third investigator-initiated study on dual anti-HER2 therapy with trastuzumab and lapatinib with chemotherapy also had an impact on research worldwide. I am currently leading other research trials, both locally and internationally. From these studies and others, I have also focused on the unique cardiac toxicities of anthracyclines and anti-HER2 agents. To allow for improved patient selection and monitoring, I am studying cardiac biomarkers, with a future goal of facilitating early interventions to minimize acute and late cardiac effects of cancer treatment.

New therapies have greatly improved the prognosis for many breast cancer patients, but some treatments produce side effects that appear years after the completion of treatment. My colleagues and I are working to develop markers or predictors to identify the patients who may be at risk of developing early, and possibly late, complications such as heart damage so that we can design early interventions to prevent these side effects — for example, by adding a cardiac drug to treatment to minimize heart problems in the future.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

Clinical Trials

Smiling doctors in the lab

Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Research and Publications

Publications on PubMed

Visit PubMed for a full listing of Dr. Dang’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.